|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
C
|
|
INDICATIONS:
|
|
|
|
SIDE EFFECTS:
|
|
Chest pain, severe |
|
difficulty in swallowing |
|
heaviness, tightness, or pressure in chest and/or neck |
|
Anaphylactic or anaphylactoid reaction |
|
dermatitis, allergic |
|
seizures |
|
Injection site reaction |
|
irritation in the nose |
|
nausea or vomiting |
|
taste perversion |
|
Atypical sensations |
|
discomfort in jaw, mouth, throat, tongue, nasal cavity, or sinuses |
|
dizziness |
|
drowsiness |
|
flushing |
|
lightheadedness |
|
muscle aches, cramps, or stiffness |
|
weakness |
|
Anxiety |
|
general feeling of illness or tiredness |
|
vision changes |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
Cardiac arrhythmias |
|
>> Tachycardia |
|
>> Cerebrovascular accident |
|
>> Coronary artery disease, predisposition to |
|
>> Hepatic function impairment |
|
Renal function impairment |
|
Hypertension, controlled |
|
|
ADULT DOSE:
|
|
Antimigraine agent-
Subcutaneous, injected into the outer thigh or the outer upper arm, 6 mg (base). If a beneficial response to this dose is obtained within one or two hours, an additional 6-mg dose may be administered, at least one hour after the first dose, if headache pain returns or increases in severity.
Note: Lower doses may be administered if the patient does not tolerate the usual dose. The auto-injector should not be used for this purpose; doses should be withdrawn from the single-dose vial, using a separate syringe.
One study compared the effects of 6-mg and 8-mg subcutaneous doses of sumatriptan (base) in migraineurs. The 8-mg dose was not significantly more effective than the 6-mg dose; therefore, doses higher than 6 mg are not recommended. |
|
MAXIMUM ADULT DOSE:
|
|
Antimigraine agent-
Single subcutaneous doses should not exceed 6 mg (base). No more than two 6-mg doses should be administered within twenty-four hours .
Note: Some clinicians recommend administering no more than two 6-mg doses within forty-eight hours . |
|
PEDIATRIC DOSE:
|
|
Safety and efficacy in patients up to 18 years of age have not been established .
|
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|
|